文献速递临床试验与 GCP

预防性放疗用于轻微症状脊柱病变(PROMISSeD):一项随机对照试验的研究方案

Prophylactic Radiotherapy Of MInimally Symptomatic Spinal Disease (PROMISSeD): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2024-01-12

这是一项单中心、平行臂、进行中的随机对照试验,纳入ECOG 0-2分、无症状或轻微症状(不需阿片类)、影像学转移灶>5处的高危脊柱转移成人患者,1:1随机接受标准全身治疗或早期放疗(20-30 Gy/2-10次)联合标准全身治疗,主要终点为1年内骨相关事件(SRE)。计划2年入组74例,以双样本比例检验达到>80%把握度(α<0.05)。

要点

  • 高危脊柱转移定义为:最大病灶≥2 cm、交界区病变、后柱受累或椎体压缩畸形>50%。
  • 主要终点SRE为复合结局,含脊柱骨折、脊髓压迫、需姑息放疗、介入操作或脊柱手术。
  • 计划入组74例,2年完成,双样本比例检验α<0.05时把握度>80%。

核心结论

  • 该随机对照试验结果将展示早期放疗对高危脊柱转移的潜在价值(如有)。
  • 若结果为阳性,试验将拓展脊柱放疗的适用范围和效用。

研究设计与样本

  • 单中心、平行臂、进行中的随机对照试验,纳入年龄≥18岁、ECOG体能状态0-2分、组织学确诊的实体瘤恶性肿瘤且横断面影像显示转移灶>5处的无症状或轻微症状(不需阿片类)高危脊柱转移成人患者。
  • 高危脊柱转移定义:最大病灶≥2 cm;交界区病变(枕骨至C2、C7-T1、T12-L2、L5-S1);后柱受累;或椎体压缩畸形>50%。
  • 患者1:1随机接受标准全身治疗(第1臂)或早期对≤5个高危脊柱病灶放疗(20-30 Gy,2-10次)联合标准全身治疗(第2臂)。
  • 计划2年入组74例,以双样本比例检验α<0.05达到>80%把握度检测差异。
  • 试验已获IRB批准、资助并前瞻性注册(NCT05534321),自2022年8月19日起开放入组。

关键数值与推荐

  • 主要终点SRE为复合结局,包括脊柱骨折、脊髓压迫、需姑息放疗、介入操作或脊柱手术。
  • 次要终点包括:SRE相关住院次数和时长等医疗费用替代指标;总生存期;无痛生存期;生活质量。
  • 研究工具将在治疗前、基线、治疗期间及治疗后1、3、6、12和24个月采集。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early palliative/pre-emptive intervention improves clinical outcomes and quality of life for patients with metastatic cancer. A previous signal-seeking randomized controlled trial (RCT) demonstrated that early upfront radiotherapy to asymptomatic or minimally symptomatic high-risk osseous metastases led to reduction in skeletal-related events (SREs), a benefit driven primarily by subgroup of high-risk spine metastasis. The current RCT aims to determine whether early palliative/pre-emptive radiotherapy in patients with high-risk, asymptomatic or minimally symptomatic spine metastases will lead to fewer SREs within 1 year. METHODS: This is a single-center, parallel-arm, in-progress RCT in adults (≥ 18 years) with ECOG performance status 0-2 and asymptomatic or minimally symptomatic (not requiring opioids) high-risk spine metastases from histologically confirmed solid tumor malignancies with > 5 sites of metastatic disease on cross-sectional imaging. High-risk spine metastases are defined by the following: (a) bulkiest disease sites ≥ 2 cm; (b) junctional disease (occiput to C2, C7-T1, T12-L2, L5-S1); (c) posterior element involvement; or (d) vertebral body compression deformity > 50%. Patients are randomized 1:1 to receive either standard-of-care systemic therapy (arm 1) or upfront, early radiotherapy to ≤ 5 high-risk spine lesions plus standard-of-care systemic therapy (arm 2), in the form of 20-30 Gy of radiation in 2-10 fractions. The primary endpoint is SRE, a composite outcome including spinal fracture, spinal cord compression, need for palliative radiotherapy, interventional procedures, or spinal surgery. Secondary endpoints include (1) surrogates of health care cost, including the number and duration of SRE-related hospitalizations; (2) overall survival; (3) pain-free survival; and (4) quality of life. Study instruments will be captured pre-treatment, at baseline, during treatment, and at 1, 3, 6, 12, and 24 months post-treatment. The trial aims to accrue 74 patients over 2 years to achieve > 80% power in detecting difference using two-sample proportion test with alpha < 0.05. DISCUSSION: The results of this RCT will demonstrate the value, if any, of early radiotherapy for high-risk spine metastases. The trial has received IRB approval, funding, and prospective registration (NCT05534321) and has been open to accrual since August 19, 2022. If positive, the trial will expand the scope and utility of spine radiotherapy. TRIAL REGISTRATION: ClinicalTrials.Gov NCT05534321 . Registered September 9, 2022. TRIAL STATUS: Version 2.0 of the protocol (2021-KOT-002), revised last on September 2, 2022, was approved by the WCG institutional review board (Study Number 1337188, IRB tracking number 20223735). The trial was first posted on ClinicalTrials.Gov on September 9, 2022 (NCT05534321). Patient enrollment commenced on August 19, 2022, and is expected to be completed in 2 years, likely by August 2024.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Rothrock RJ, Ozair A, Avendano MC, et al. Prophylactic Radiotherapy Of MInimally Symptomatic Spinal Disease (PROMISSeD): study protocol for a randomized controlled trial. Trials. 2024. PMID: 38217032. doi:10.1186/s13063-023-07850-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。